Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 12, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01763-17
Keywords
HIV; antiretroviral therapy; CD4/CD8ratio; T cells; T-cell activation; efavirenz; maraviroc
Categories
Funding
- ViiV
- Spanish Ministry of Economy and Competitiveness [JR14/0004]
- SPANISH AIDS Research Network (RIS) as part of Plan Nacional R+D+I [RD16/0025/0001]
- ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER)
Ask authors/readers for more resources
A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8(+) T-cell decline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
